Topic: corporate governance
Sanofi CEO Paul Hudson hinted at a coming shakeup—from diabetes to cancer and R&D to marketing. And he's planning to unveil those plans December 10.
Novartis needs to trace its ethics woes to their roots and apply its stated values to real-life decisions, experts say. Even then, change takes time.
AbbVie investors are calling for a separation of powers between its board chairman and CEO roles following congressional scrutiny and patent fights over its drug Humira.
A Sun distributor allegedly inked transactions worth $816 million with a firm controlled by Sun’s co-promoter Sudhir Valia.
Though managing director Dilip Shanghvi tried to allay investors' concerns, a couple of key questions remain unanswered.
AstraZeneca slashed CEO Pascal Soriot’s total pay by 34% in 2017, but that cut wasn’t deep enough for one influential voice on corporate governance.
Eli Lilly is moving to a new marketing model to manage expenses, but will ad agencies lose work as Lilly looks to bring more services in-house?
It's official: GlaxoSmithKline CEO Andrew Witty is moving on. At the helm of the U.K.-based drugmaker since 2008, Witty will step down in March 2017, clearing the way for a new captain to chart a new course.